Trasylol-Injury-Lawyers.com: 09-12-2007 | ADDENDUM To the Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part A

Contact Us

Contact us today.

Articles

11-07-2007 | Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part B
11-05-2007 | Bayer Temporarily Suspends Global Trasylol® (aprotinin injection) Marketing
10-25-2007 | Bayer Issues Additional Guidance to Physicians on Trasylol® (aprotinin injection)
09-12-2007 | FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
09-12-2007 | Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part A
09-12-2007 | ADDENDUM To the Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part A
08-16-2007 | Bayer Reports Findings of Trasylol Independent Investigation
02-26-2007 | Bayer Responds to study and commentary published in Journal of American Medical Association (JAMA)
01-25-2007 | Bayer Pharmaceuticals Trasylol® (aprotinin injection) Press Release
12-15-2006 | Bayer Pharmaceuticals Trasylol® (aprotinin injection) Press Release
10-13-2006 | Bayer Appoints Independent Investigator to Review Trasylol® Study Issues
10-02-2006 | Current Trasylol® (aprotinin injection) News
09-29-2006 | Bayer Acknowledges That New Trasylol Study Was Not Disclosed Prior to Recent FDA Cardio-Renal Advisory Committee Meeting.

Headlines

09-12-2007 | ADDENDUM To the Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part A

September 12, 2007

Report on Computerized Inpatient Data from the Premier Perspective Comparative Database. Continue reading, ‘09-12-2007 | ADDENDUM To the Final Report: Risks of Renal Failure and Death following Use of Aprotinin or Aminocaproic Acid during CABG Surgery Part A.’